Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet).